CA
ORIC icon

Clearstead Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

Clearstead Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98 Buy
+9
New +$82 ﹤0.01% 3360
2025
Q3 		– Sell
-4
Closed -$41 – 3201
2025
Q2 		$41 Buy
+4
New +$27 ﹤0.01% 2683

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Clearstead Advisors's ORIC Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Oric Pharmaceuticals (ORIC) in Q2 2026: 9 shares worth $98. The stake represents ﹤0.01% of the portfolio and ranks #3360 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in ORIC as recently as Q2 2025.

Clearstead Advisors first reported a position in ORIC in Q2 2025 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Clearstead Advisors held 9 shares of Oric Pharmaceuticals worth $98 as of Q2 2026.
  • Oric Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
  • Oric Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3360 holding.
  • Clearstead Advisors first reported a position in Oric Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.